Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Olsson (Hannover, Germany), M. Richter (Gießen , Germany), J. Kamp (Hannover, Germany), H. Gall (Gießen, Germany), A. Heine (Greifswald, Germany), H. Ghofrani (Greifswald, Germany), J. Fuge (Hannover, Germany), R. Ewert (Greifswald, Germany), M. Hoeper (Greifswald, Germany). Risk assessment and prognosis in patients with pulmonary arterial hypertension receiving intravenous treprostinil. 499

Member's Comments

No comment yet.

Related content which might interest you: Long-term safety and outcome of subcutaneous and intravenous treprostinil in patients with severe chronic pulmonary hypertension Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside Year: 2019 Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Source: Eur Respir J 2006; 28: 1195-1203 Year: 2006 Assessment of satisfaction in patients with pulmonary hypertension treated with epoprostenol Source: Annual Congress 2008 - Pulmonary arterial hypertension and other pulmonary vascular diseases Year: 2008 Successful pregnancy outcome in patients with pulmonary arterial hypertension receiving prostayclin therapy Source: Annual Congress 2004 - Pulmonary hypertension Year: 2004 Experience with subcutaneous treprostinil in children with pulmonary arterial hypertension Source: International Congress 2017 – NICU/ PICU: evaluating short- and long-term ventilatory management Year: 2017 Low dose intravenous iloprost therapy in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 426s Year: 2006 Long-term continuous subcutaneous treprostinil therapy for pulmonary arterial hypertension (PAH) Source: Eur Respir J 2003; 22: Suppl. 45, 461s Year: 2003 Long-term outcome with intravenous iloprost in pulmonary arterial hypertension Source: Eur Respir J 2009; 34: 132-137 Year: 2009 Risk assessment, therapy and cardiovascular comorbidity in patients with pulmonary arterial hypertension Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension Year: 2020 One-year observation of iloprost inhalation therapy in patients with pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 324s Year: 2001 Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary arterial hypertension (PAH) Source: Eur Respir J 2003; 22: Suppl. 45, 563s Year: 2003 Parenteral treprostinil for significant pulmonary arterial hypertension associated with pulmonary fibrosis: A safety study Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020 Year: 2020 Risk stratification and medical therapy of pulmonary arterial hypertension Source: Eur Respir J, 53 (1) 1801889; 10.1183/13993003.01889-2018 Year: 2019 Response to exercise in patients with pulmonary arterial hypertension treated with combination therapy Source: ERJ Open Res, 7 (1) 00725-2020; 10.1183/23120541.00725-2020 Year: 2021 Population pharmacokinetics of imatinib in patients with pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Long-term treatment with oral sildenafil in addition to chronic prostacyclin therapy improves pulmonary hemodynamics and six minute walking test in patients with pulmonary arterial hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 598s Year: 2002 Patterns of therapy with sildenafil among patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010